Biomaterial Database

Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. 2022

Jinyu Wang, and Michela Manni, and Anne Bärenwaldt, and Ronja Wieboldt, and Nicole Kirchhammer, and Robert Ivanek, and Michal Stanczak, and Alfred Zippelius, and David König, and Natalia Rodrigues Manutano, and Heinz Läubli

Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.

Interactions between sialylated glycans and sialic acid-binding immunoglobulin-like lectin (Siglec) receptors have been recently described as potential new immune checkpoint that can be targeted to improve anticancer immunity. Myeloid cells have been reported to express a wide range of different Siglecs; however, their expression and functions on cancer-associated dendritic cells (DCs) were not fully characterized. We found that classical conventional DCs (cDCs) from cancer patient samples have a high expression of several inhibitory Siglecs including Siglec-7, Siglec-9, and Siglec-10. In subcutaneous murine tumor models, we also found an upregulation of the inhibitory Siglec-E receptor on cancer-associated cDCs. DC lines and bone marrow-derived DCs (BMDCs) with expression of these inhibitory Siglecs showed impaired maturation states on transcriptome and protein level. Furthermore, ablation of these inhibitory Siglecs from DCs enhanced their capability to prime antigen-specific T cells and induce proliferation. Our work provides a deeper understanding of the influence of inhibitory Siglecs on DCs and reveals a potential new target to improve cancer immunotherapy.